<DOC>
	<DOCNO>NCT02807636</DOCNO>
	<brief_summary>A Phase III , randomise study atezolizumab alone combination chemotherapy versus chemotherapy alone participant untreated advanced urothelial cancer .</brief_summary>
	<brief_title>Study Atezolizumab Monotherapy Combination With Platinum-Based Chemotherapy Participants With Untreated Locally Advanced Metastatic Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Considered eligible receive platinumbased chemotherapy , investigator 's judgment Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; /= ) 2 Histologically document , locally advanced ( T4b , N ; T , N23 ) metastatic urothelial carcinoma ( mUC ) ( M1 , Stage IV ) ( also term transitional cell carcinoma [ TCC ] urothelial cell carcinoma [ UCC ] urinary tract ; include renal pelvis , ureter , urinary bladder , urethra ) Representative formalinfixed paraffinembedded ( FFPE ) tumor specimens paraffin block ( block prefer ) least 15 unstained slide , associate pathology report , central test determine evaluable tumor PDL1 expression prior study enrollment ; participant fewer 15 unstained slide available baseline ( less [ &lt; ] 10 ) may eligible follow discussion Medical Monitor No prior chemotherapy inoperable locally advanced mUC For participant receive prior adjuvant/neoadjuvant chemotherapy chemoradiation urothelial carcinoma , treatmentfree interval ( &gt; ) 12 month last treatment administration date recurrence require order consider treatment naive metastatic set Prior local intravesical chemotherapy immunotherapy allow complete least 4 week prior initiation study treatment Measurable disease , define RECIST v1.1 Adequate hematologic endorgan function For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate &lt; 1 % per year treatment period least 6 month last dose carboplatin , cisplatin , gemcitabine 5 month last dose atezolizumab For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure agreement refrain donate sperm Any approve anticancer therapy , include chemotherapy hormonal therapy , within 3 week prior initiation study treatment Treatment investigational agent participation another clinical study therapeutic intent within 28 day prior enrolment Active untreated CNS metastasis determine compute tomography ( CT ) magnetic resonance image evaluation screen prior radiographic assessment Participants treat asymptomatic central nervous system ( CNS ) metastases eligible , provide meet follow criterion : * Evaluable measurable disease outside CNS * No metastases midbrain , pons , medulla , within 10 mm optic apparatus ( optic nerve chiasm ) * No history intracranial spinal cord hemorrhage * No ongoing requirement corticosteroid therapy CNS disease ; anticonvulsant stable dose allow * No evidence significant vasogenic edema * No stereotactic radiation , wholebrain radiation neurosurgical resection within 4 week prior Cycle 1 , Day 1 * Radiographic demonstration interim stability ( i.e. , progression ) completion CNSdirected therapy screen radiographic study * Screening CNS radiographic study &gt; /=4 week since completion radiotherapy surgical resection &gt; /=2 week since discontinuation corticosteroid Prior treatment CD137 agonist , antiCTLA4 , antiprogrammed death1 ( PD1 ) , antiPDL1 therapeutic antibody pathwaytargeting agent Treatment systemic corticosteroid systemic immunosuppressive medication ( include limit prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ TNF ] agent ) within 2 week prior Cycle 1 , Day 1 anticipate requirement systemic immunosuppressive medication study Leptomeningeal disease Uncontrolled pleural effusion , pericardial effusion , ascites require recurrent drainage procedure ( monthly frequently ) Uncontrolled tumourrelated pain hypercalcemia Significant cardiovascular disease include know left ventricular ejection fraction ( LVEF ) &lt; 40 % Severe infection within 4 week randomization therapeutic oral IV antibiotic within 2 week randomization Major surgical procedure within 4 week prior randomization anticipation need major surgical procedure course study diagnosis Malignancies urothelial carcinoma within 5 year prior Cycle 1 , Day 1 Life expectancy &lt; 12 week Pregnant lactating , intend become pregnant study Serum albumin &lt; 25 gram per liter ( g/L ) History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein Known hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation History autoimmune disease Participants prior allogeneic stem cell solid organ transplantation History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia ) , evidence active pneumonitis screen chest CT scan Positive test human immunodeficiency virus ( HIV ) Active hepatitis B hepatitis C Active tuberculosis Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>Bladder cancer</keyword>
	<keyword>Anti-PD-L1</keyword>
	<keyword>Transitional carcinoma</keyword>
	<keyword>Tecentriq</keyword>
	<keyword>Atezolizumab</keyword>
	<keyword>IMvigor130</keyword>
</DOC>